Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) Stock Competitors & Peer Comparison
See HROWM's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HROWM and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| RPRX | $66.52 | -0.98% | 29.6B | 12.67 | $5.25 | +1.38% |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| CORT | $80.46 | -0.81% | 8.7B | 229.89 | $0.35 | N/A |
| KNSA | $90.80 | -1.56% | 7.1B | 69.77 | $1.30 | N/A |
| LQDA | $41.85 | -7.12% | 3.7B | 30.55 | $1.37 | N/A |
| PBH | $49.73 | +1.37% | 2.4B | 11.26 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| LTGO | $13.51 | -3.15% | 811.5M | -5.35 | -$2.52 | N/A |
| HELP | $8.80 | -16.94% | 545.5M | -2.11 | -$4.16 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
HROWM vs RPRX Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, RPRX has a market cap of 29.6B. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while RPRX trades at $66.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 12.67. In terms of profitability, HROWM's ROE is -1.04%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, HROWM is less volatile compared to RPRX. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check RPRX's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
HROWM vs WBA Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas WBA's P/E ratio is -1.64. In terms of profitability, HROWM's ROE is -1.04%, compared to WBA's ROE of -0.57%. Regarding short-term risk, HROWM is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for HROWM.Check WBA's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
HROWM vs CORT Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CORT has a market cap of 8.7B. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while CORT trades at $80.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 229.89. In terms of profitability, HROWM's ROE is -1.04%, compared to CORT's ROE of +0.08%. Regarding short-term risk, HROWM is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check CORT's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
HROWM vs KNSA Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, KNSA has a market cap of 7.1B. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while KNSA trades at $90.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 69.77. In terms of profitability, HROWM's ROE is -1.04%, compared to KNSA's ROE of +0.17%. Regarding short-term risk, HROWM is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
HROWM vs LQDA Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, LQDA has a market cap of 3.7B. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while LQDA trades at $41.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is 30.55. In terms of profitability, HROWM's ROE is -1.04%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, HROWM is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
HROWM vs PBH Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, PBH has a market cap of 2.4B. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while PBH trades at $49.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas PBH's P/E ratio is 11.26. In terms of profitability, HROWM's ROE is -1.04%, compared to PBH's ROE of +0.09%. Regarding short-term risk, HROWM is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
HROWM vs HROWL Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas HROWL's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -1.04%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, HROWM is less volatile compared to HROWL. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check HROWL's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
HROWM vs LTGO Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, LTGO has a market cap of 811.5M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while LTGO trades at $13.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas LTGO's P/E ratio is -5.35. In terms of profitability, HROWM's ROE is -1.04%, compared to LTGO's ROE of N/A. Regarding short-term risk, HROWM is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check LTGO's competition here
Helus Pharma Inc. (NASDAQ: HELP)
HROWM vs HELP Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, HELP has a market cap of 545.5M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while HELP trades at $8.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas HELP's P/E ratio is -2.11. In terms of profitability, HROWM's ROE is -1.04%, compared to HELP's ROE of -0.71%. Regarding short-term risk, HROWM is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
HROWM vs SVA Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas SVA's P/E ratio is -5.68. In terms of profitability, HROWM's ROE is -1.04%, compared to SVA's ROE of -0.01%. Regarding short-term risk, HROWM is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for HROWM.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
HROWM vs CUVL Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CUVL has a market cap of 249.9M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while CUVL trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CUVL's P/E ratio is 10.68. In terms of profitability, HROWM's ROE is -1.04%, compared to CUVL's ROE of N/A. Regarding short-term risk, HROWM is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check CUVL's competition here
High Tide Inc. (NASDAQ: HITI)
HROWM vs HITI Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, HITI has a market cap of 230.9M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while HITI trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas HITI's P/E ratio is -9.57. In terms of profitability, HROWM's ROE is -1.04%, compared to HITI's ROE of -0.36%. Regarding short-term risk, HROWM is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check HITI's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
HROWM vs CELG-RI Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CELG-RI has a market cap of 194.1M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while CELG-RI trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -1.04%, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, HROWM is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for HROWM.Check CELG-RI's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
HROWM vs ETRA Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, ETRA has a market cap of 155.1M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while ETRA trades at $7.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas ETRA's P/E ratio is -2.76. In terms of profitability, HROWM's ROE is -1.04%, compared to ETRA's ROE of N/A. Regarding short-term risk, HROWM is less volatile compared to ETRA. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check ETRA's competition here
TRex Bio Inc. (NASDAQ: TRXB)
HROWM vs TRXB Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, TRXB has a market cap of 114.4M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while TRXB trades at $13.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas TRXB's P/E ratio is -5.56. In terms of profitability, HROWM's ROE is -1.04%, compared to TRXB's ROE of N/A. Regarding short-term risk, HROWM is less volatile compared to TRXB. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check TRXB's competition here
Atlantic International Corp. (NASDAQ: ATLN)
HROWM vs ATLN Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, ATLN has a market cap of 68.6M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas ATLN's P/E ratio is -0.68. In terms of profitability, HROWM's ROE is -1.04%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, HROWM is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check ATLN's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
HROWM vs CTOR Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CTOR has a market cap of 55.2M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while CTOR trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CTOR's P/E ratio is -1.26. In terms of profitability, HROWM's ROE is -1.04%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, HROWM is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check CTOR's competition here
Retension Pharmaceuticals Inc. (NASDAQ: RTSN)
HROWM vs RTSN Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, RTSN has a market cap of 43.6M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while RTSN trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas RTSN's P/E ratio is -4.45. In terms of profitability, HROWM's ROE is -1.04%, compared to RTSN's ROE of N/A. Regarding short-term risk, HROWM is less volatile compared to RTSN. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check RTSN's competition here
Rite Aid Corporation (NYSE: RAD)
HROWM vs RAD Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas RAD's P/E ratio is -0.05. In terms of profitability, HROWM's ROE is -1.04%, compared to RAD's ROE of +2.76%. Regarding short-term risk, HROWM is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
HROWM vs GLTO Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas GLTO's P/E ratio is -1.78. In terms of profitability, HROWM's ROE is -1.04%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, HROWM is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check GLTO's competition here
Cosmos Health Inc. (NASDAQ: COSM)
HROWM vs COSM Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, COSM has a market cap of 31.1M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while COSM trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas COSM's P/E ratio is -0.42. In terms of profitability, HROWM's ROE is -1.04%, compared to COSM's ROE of -1.19%. Regarding short-term risk, HROWM is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check COSM's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
HROWM vs NSRX Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, NSRX has a market cap of 27.6M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while NSRX trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas NSRX's P/E ratio is -4.44. In terms of profitability, HROWM's ROE is -1.04%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, HROWM is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
HROWM vs SCYX Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, SCYX has a market cap of 24M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while SCYX trades at $3.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas SCYX's P/E ratio is -1.11. In terms of profitability, HROWM's ROE is -1.04%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, HROWM is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check SCYX's competition here
Pomdoctor Limited (NASDAQ: POM)
HROWM vs POM Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, POM has a market cap of 16.4M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while POM trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas POM's P/E ratio is -0.28. In terms of profitability, HROWM's ROE is -1.04%, compared to POM's ROE of +0.80%. Regarding short-term risk, HROWM is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check POM's competition here
Biofrontera Inc. (NASDAQ: BFRI)
HROWM vs BFRI Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, BFRI has a market cap of 13M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while BFRI trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas BFRI's P/E ratio is -1.59. In terms of profitability, HROWM's ROE is -1.04%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, HROWM is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check BFRI's competition here
Cerenome, Inc. (NASDAQ: CNSY)
HROWM vs CNSY Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CNSY has a market cap of 12.9M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while CNSY trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CNSY's P/E ratio is -0.41. In terms of profitability, HROWM's ROE is -1.04%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, HROWM is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check CNSY's competition here
Azora Therapeutics, Inc. (NASDAQ: AZR)
HROWM vs AZR Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, AZR has a market cap of 10.4M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while AZR trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas AZR's P/E ratio is -0.24. In terms of profitability, HROWM's ROE is -1.04%, compared to AZR's ROE of N/A. Regarding short-term risk, HROWM is less volatile compared to AZR. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check AZR's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
HROWM vs CJJD Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CJJD's P/E ratio is -0.46. In terms of profitability, HROWM's ROE is -1.04%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, HROWM is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
HROWM vs SSY Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas SSY's P/E ratio is -2.86. In terms of profitability, HROWM's ROE is -1.04%, compared to SSY's ROE of -0.09%. Regarding short-term risk, HROWM is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check SSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
HROWM vs SCNX Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, SCNX has a market cap of 5.3M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while SCNX trades at $3.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas SCNX's P/E ratio is -1.54. In terms of profitability, HROWM's ROE is -1.04%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, HROWM is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check SCNX's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
HROWM vs BGMS Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, BGMS has a market cap of 5M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while BGMS trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas BGMS's P/E ratio is -0.25. In terms of profitability, HROWM's ROE is -1.04%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, HROWM is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check BGMS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
HROWM vs MDVL Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas MDVL's P/E ratio is -0.05. In terms of profitability, HROWM's ROE is -1.04%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, HROWM is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check MDVL's competition here
Eocene Ltd. (NASDAQ: EOCN)
HROWM vs EOCN Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, EOCN has a market cap of 2.8M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while EOCN trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas EOCN's P/E ratio is -0.19. In terms of profitability, HROWM's ROE is -1.04%, compared to EOCN's ROE of N/A. Regarding short-term risk, HROWM is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check EOCN's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
HROWM vs PAVS Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, PAVS has a market cap of 2.7M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while PAVS trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas PAVS's P/E ratio is -0.03. In terms of profitability, HROWM's ROE is -1.04%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, HROWM is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check PAVS's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
HROWM vs ATNFW Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas ATNFW's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -1.04%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, HROWM is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
HROWM vs BGMSP Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, HROWM's ROE is -1.04%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, HROWM is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
HROWM vs AZNH Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas AZNH's P/E ratio is 38.35. In terms of profitability, HROWM's ROE is -1.04%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, HROWM is less volatile compared to AZNH. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check AZNH's competition here
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP)
HROWM vs ASBP Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, ASBP has a market cap of 842.2K. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while ASBP trades at $7.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas ASBP's P/E ratio is -0.31. In terms of profitability, HROWM's ROE is -1.04%, compared to ASBP's ROE of +19.93%. Regarding short-term risk, HROWM is less volatile compared to ASBP. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check ASBP's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
HROWM vs BFRIW Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, BFRIW has a market cap of 796.7K. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while BFRIW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas BFRIW's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -1.04%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, HROWM is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for HROWM.Check BFRIW's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
HROWM vs LFLYW Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, HROWM's ROE is -1.04%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, HROWM is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for HROWM.Check LFLYW's competition here
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBPW)
HROWM vs ASBPW Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, ASBPW has a market cap of 149.5K. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while ASBPW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas ASBPW's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -1.04%, compared to ASBPW's ROE of +19.93%. Regarding short-term risk, HROWM is less volatile compared to ASBPW. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check ASBPW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
HROWM vs PRPH Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, PRPH has a market cap of 91.1K. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas PRPH's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -1.04%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, HROWM is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check PRPH's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
HROWM vs OREX Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, OREX has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas OREX's P/E ratio is -0.14. In terms of profitability, HROWM's ROE is -1.04%, compared to OREX's ROE of -0.54%. Regarding short-term risk, HROWM is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check OREX's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
HROWM vs ESRX Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas ESRX's P/E ratio is 10.69. In terms of profitability, HROWM's ROE is -1.04%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, HROWM is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for HROWM.Check ESRX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
HROWM vs IPXL Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas IPXL's P/E ratio is -10.11. In terms of profitability, HROWM's ROE is -1.04%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, HROWM is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check IPXL's competition here
Shire plc (NASDAQ: SHPG)
HROWM vs SHPG Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas SHPG's P/E ratio is 11.35. In terms of profitability, HROWM's ROE is -1.04%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, HROWM is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for HROWM.Check SHPG's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
HROWM vs CPD Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CPD has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CPD's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -1.04%, compared to CPD's ROE of N/A. Regarding short-term risk, HROWM is less volatile compared to CPD. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check CPD's competition here
POZEN Inc. (NASDAQ: POZN)
HROWM vs POZN Comparison November 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, POZN has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas POZN's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -1.04%, compared to POZN's ROE of +0.61%. Regarding short-term risk, HROWM is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check POZN's competition here